Company news
Apollomics Inc. news in 2024
Apollomics Inc.'s news releases, calls and decks from 2024, newest first.
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
December 19, 2024
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
December 11, 2024
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
December 9, 2024
Apollomics Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
November 22, 2024
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
November 20, 2024
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
September 15, 2024
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
August 13, 2024
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
August 12, 2024
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
July 15, 2024
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
July 2, 2024
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 3, 2024
Apollomics Announces Presentation at the 2024 BIO International Convention
May 28, 2024
Apollomics Announces Private Placement Financing and Addition to Board of Directors
May 7, 2024
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
April 24, 2024
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 9, 2024
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 1, 2024
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
March 27, 2024
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
March 25, 2024
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
March 3, 2024
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
January 2, 2024